MD+DI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Lack of Recognition is Part of the Problem

At least when it comes to treating abdominal aortic aneurysms (AAA). Did you know that deaths as a result of AAA are just as common as those from prostate and breast cancer? New tools are raising the bar in terms of what doctors can do, making good surgeons excellent and excellent surgeons phenomenal ones, according to Mark Farber, a physician who spoke at a media and investor event held by Cook Medical yesterday afternoon in New York City. Cook is one of three major companies leading the way in treating AAA.

In fact, the company has exceeded its own expectations in global sales this year and now leads the worldwide market in endovascular aortic repair. By the end of the third quarter, Cook surpassed Gore and captured 40% of the U.S. market (Gore had 35% and Medtronic held 23%). In Europe, Cook took the top spot in AAA stent grafts at 42%. The company is working on several projects for its Zenith Endograft product family for 2008. We can expect to see several clinical trials, PMA submissions, and even product launches in the coming year as Cook tries to keep a tight grip on the market.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.